Dr. Randeep Guleria, a distinguished pulmonologist and former director of AIIMS, stated on Saturday that although the new COVID-19 sub-variant JN.1 is more transmissible, it is not leading to serious infections or hospital admissions. He claims that the variation is progressively taking over.
It is more contagious, spreading faster and eventually taking over as the predominant variation. Although the evidence indicates that it is not leading to serious infections or hospitalisations, it is nevertheless generating more illnesses. Dr. Guleria informed news agency ANI that the majority of the symptoms, which include fever, cough, cold, sore throat, running nose, and body aches, are primarily in the upper airways.
The World Health Organisation (WHO) has designated the JN.1 variety, a progenitor of the Omicron virus, as a “variant of interest.” The global health organisation did, however, stress that, according to available data, the overall danger posed by JN.1 is still minimal.
Chief of the India SARS-CoV-2 Genomics Consortium (INSACOG), Dr. NK Arora, states that at this time, a second dose of the JN.1 vaccination is not required. “I would recommend that everyone 60 years of age or older, those with comorbidities, and those on medications that lower immunity, such as cancer patients, practice prevention. According to ANI, he said, “If they haven’t taken precautions already, then they should take precautions; otherwise, there is no need for any additional doses.”
India’s version of JN.1
Up to 22 cases of the novel COVID variety have been documented in India thus far, raising fears throughout the nation. Keralan authorities discovered the first instance in a 79-year-old woman. Of the 20 cases, 19 have been found in Goa, one each in Kerala and Maharashtra, and one whose specifics have not yet been made public.
In the meantime, India recorded 752 cases in a 24-hour period on Saturday, marking the largest increase in a single day since May 21. There were 3,420 cases that were still pending.
(In collaboration with ANI)
